-DOCSTART- -X- O
Ebola -X- _ O
virus -X- _ O
infections -X- _ O
lead -X- _ O
to -X- _ O
severe -X- _ O
hemorrhagic -X- _ O
fevers -X- _ O
in -X- _ O
humans -X- _ O
and -X- _ O
nonhuman -X- _ O
primates -X- _ O
; -X- _ O
and -X- _ O
human -X- _ O
fatality -X- _ O
rates -X- _ O
are -X- _ O
as -X- _ O
high -X- _ O
as -X- _ O
67 -X- _ O
% -X- _ O
–90 -X- _ O
% -X- _ O
. -X- _ O
Since -X- _ O
the -X- _ O
Ebola -X- _ O
virus -X- _ O
was -X- _ O
discovered -X- _ O
in -X- _ O
1976 -X- _ O
, -X- _ O
the -X- _ O
only -X- _ O
available -X- _ O
treatments -X- _ O
have -X- _ O
been -X- _ O
medical -X- _ O
support -X- _ O
or -X- _ O
the -X- _ O
emergency -X- _ O
administration -X- _ O
of -X- _ O
experimental -X- _ O
drugs. -X- _ O
The -X- _ O
absence -X- _ O
of -X- _ O
licensed -X- _ O
vaccines -X- _ O
and -X- _ O
drugs -X- _ O
against -X- _ O
the -X- _ O
Ebola -X- _ O
virus -X- _ O
impedes -X- _ O
the -X- _ O
prevention -X- _ O
of -X- _ O
viral -X- _ O
infection. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
generated -X- _ O
recombinant -X- _ B-Intervention
baculoviruses -X- _ I-Intervention
( -X- _ I-Intervention
rBV -X- _ I-Intervention
) -X- _ I-Intervention
expressing -X- _ I-Intervention
the -X- _ I-Intervention
Sudan -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
SUDV -X- _ I-Intervention
) -X- _ I-Intervention
matrix -X- _ I-Intervention
structural -X- _ I-Intervention
protein -X- _ I-Intervention
( -X- _ I-Intervention
VP40 -X- _ I-Intervention
) -X- _ I-Intervention
( -X- _ I-Intervention
rBV-VP40-VP40 -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ I-Intervention
the -X- _ I-Intervention
SUDV -X- _ I-Intervention
glycoprotein -X- _ I-Intervention
( -X- _ I-Intervention
GP -X- _ I-Intervention
) -X- _ I-Intervention
( -X- _ I-Intervention
rBV-GP-GP -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
SUDV -X- _ I-Intervention
virus-like -X- _ I-Intervention
particles -X- _ I-Intervention
( -X- _ I-Intervention
VLPs -X- _ I-Intervention
) -X- _ I-Intervention
were -X- _ O
produced -X- _ O
by -X- _ O
co- -X- _ O
infection -X- _ O
of -X- _ O
Sf9 -X- _ O
cells -X- _ O
with -X- _ O
rBV-SUDV-VP40 -X- _ O
and -X- _ O
rBV-SUDV-GP. -X- _ O
The -X- _ O
expression -X- _ O
of -X- _ O
SUDV -X- _ O
VP40 -X- _ O
and -X- _ O
GP -X- _ O
in -X- _ O
SUDV -X- _ O
VLPs -X- _ O
was -X- _ O
demonstrated -X- _ O
by -X- _ O
IFA -X- _ O
and -X- _ O
Western -X- _ O
blot -X- _ O
analysis. -X- _ O
Electron -X- _ O
microscopy -X- _ O
results -X- _ O
demonstrated -X- _ O
that -X- _ O
SUDV -X- _ O
VLPs -X- _ O
had -X- _ O
a -X- _ O
filamentous -X- _ O
morphology. -X- _ O
The -X- _ O
immunogenicity -X- _ O
of -X- _ O
SUDV -X- _ O
VLPs -X- _ O
produced -X- _ O
in -X- _ O
insect -X- _ O
cells -X- _ O
was -X- _ O
evaluated -X- _ O
by -X- _ O
the -X- _ O
immunization -X- _ O
of -X- _ O
mice. -X- _ B-Patient
The -X- _ O
analysis -X- _ O
of -X- _ O
antibody -X- _ O
responses -X- _ O
showed -X- _ O
that -X- _ O
mice -X- _ B-Outcome
vaccinated -X- _ I-Outcome
with -X- _ I-Outcome
SUDV -X- _ I-Outcome
VLPs -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
adjuvant -X- _ I-Outcome
Montanide -X- _ I-Outcome
ISA -X- _ I-Outcome
201 -X- _ I-Outcome
produced -X- _ I-Outcome
SUDV -X- _ I-Outcome
GP-specific -X- _ I-Outcome
IgG -X- _ I-Outcome
antibodies. -X- _ I-Outcome
Sera -X- _ I-Outcome
from -X- _ I-Outcome
SUDV -X- _ I-Outcome
VLP-immunized -X- _ I-Outcome
mice -X- _ I-Outcome
were -X- _ I-Outcome
able -X- _ I-Outcome
to -X- _ I-Outcome
block -X- _ I-Outcome
infection -X- _ I-Outcome
by -X- _ I-Outcome
SUDV -X- _ I-Outcome
GP -X- _ I-Outcome
pseudotyped -X- _ I-Outcome
HIV -X- _ I-Outcome
, -X- _ I-Outcome
indicating -X- _ I-Outcome
that -X- _ I-Outcome
a -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
against -X- _ I-Outcome
the -X- _ I-Outcome
SUDV -X- _ I-Outcome
GP -X- _ I-Outcome
protein -X- _ I-Outcome
was -X- _ I-Outcome
produced. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
activation -X- _ I-Outcome
of -X- _ I-Outcome
B -X- _ I-Outcome
cells -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
group -X- _ I-Outcome
immunized -X- _ I-Outcome
with -X- _ I-Outcome
VLPs -X- _ I-Outcome
mixed -X- _ I-Outcome
with -X- _ I-Outcome
Montanide -X- _ I-Outcome
ISA -X- _ I-Outcome
201 -X- _ I-Outcome
was -X- _ I-Outcome
significant -X- _ I-Outcome
one -X- _ I-Outcome
week -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
primary -X- _ I-Outcome
immunization. -X- _ I-Outcome
Vaccination -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
SUDV -X- _ I-Outcome
VLPs -X- _ I-Outcome
markedly -X- _ I-Outcome
increased -X- _ I-Outcome
the -X- _ I-Outcome
frequency -X- _ I-Outcome
of -X- _ I-Outcome
antigen- -X- _ I-Outcome
specific -X- _ I-Outcome
cells -X- _ I-Outcome
secreting -X- _ I-Outcome
type -X- _ I-Outcome
1 -X- _ I-Outcome
and -X- _ I-Outcome
type -X- _ I-Outcome
2 -X- _ I-Outcome
cytokines. -X- _ I-Outcome
To -X- _ O
study -X- _ O
the -X- _ O
therapeutic -X- _ O
effects -X- _ O
of -X- _ O
SUDV -X- _ O
antibodies -X- _ O
, -X- _ O
horses -X- _ B-Patient
were -X- _ O
immunized -X- _ B-Intervention
with -X- _ I-Intervention
SUDV -X- _ I-Intervention
VLPs -X- _ I-Intervention
emulsified -X- _ O
in -X- _ O
Freund’s -X- _ O
complete -X- _ O
adjuvant -X- _ O
or -X- _ O
Freund’s -X- _ O
incomplete -X- _ O
adjuvant. -X- _ O
The -X- _ O
results -X- _ O
showed -X- _ O
that -X- _ O
horses -X- _ B-Outcome
could -X- _ I-Outcome
produce -X- _ I-Outcome
SUDV -X- _ I-Outcome
GP-specific -X- _ I-Outcome
antibodies -X- _ I-Outcome
and -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies. -X- _ I-Outcome
These -X- _ O
results -X- _ O
showed -X- _ O
that -X- _ O
SUDV -X- _ B-Outcome
VLPs -X- _ I-Outcome
demonstrate -X- _ I-Outcome
excellent -X- _ I-Outcome
immunogenicity -X- _ I-Outcome
and -X- _ I-Outcome
represent -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
approach -X- _ I-Outcome
for -X- _ I-Outcome
vaccine -X- _ I-Outcome
development -X- _ I-Outcome
against -X- _ I-Outcome
SUDV -X- _ I-Outcome
infection. -X- _ I-Outcome
Further -X- _ O
, -X- _ O
these -X- _ O
horse -X- _ O
anti-SUDV -X- _ O
purified -X- _ O
immunoglobulins -X- _ O
lay -X- _ O
a -X- _ O
foundation -X- _ O
for -X- _ O
SUDV -X- _ O
therapeutic -X- _ O
drug -X- _ O
research -X- _ O
. -X- _ O

